The estimated Net Worth of Jatin Shah is at least 169 千$ dollars as of 17 February 2022. Jatin Shah owns over 1,306 units of Karyopharm Therapeutics Inc stock worth over 95,793$ and over the last 5 years he sold KPTI stock worth over 72,879$. In addition, he makes 0$ as Executive Vice President、 Chief Medical Officer at Karyopharm Therapeutics Inc.
Jatin has made over 9 trades of the Karyopharm Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 1,306 units of KPTI stock worth 15,829$ on 17 February 2022.
The largest trade he's ever made was buying 23,250 units of Karyopharm Therapeutics Inc stock on 7 May 2021 worth over 199,950$. On average, Jatin trades about 3,583 units every 56 days since 2019. As of 17 February 2022 he still owns at least 129,450 units of Karyopharm Therapeutics Inc stock.
You can see the complete history of Jatin Shah stock trades at the bottom of the page.
Dr. Jatin Shah M.D. serves as Executive Vice President, Chief Medical Officer of the Company. Dr. Shah joined Karyopharm in May 2017 as Vice President, Clinical Strategy, and was appointed Senior Vice President, Clinical Development in April 2018 and Executive Vice President, Chief Medical Officer in July 2019. Prior to joining Karyopharm, Dr. Shah held numerous roles at The University of Texas MD Anderson Cancer Center. From September 2007 to August 2016, Dr. Shah served as an Assistant Professor, Associate Professor, and Associate Program Director of the Malignant Hematology Fellowship, as well as Director of Myeloma Clinical and Translational Research in the Department of Lymphoma/Myeloma, Division of Cancer Medicine. Dr. Shah received his M.D. from The Ohio State University College of Medicine, Columbus, Ohio and holds a degree in Mechanical Engineering from The Ohio State University. Dr. Shah completed his residency in internal medicine at the Cleveland Clinic Foundation, Cleveland, Ohio, and a fellowship in hematology/oncology at the University of Alabama at Birmingham. Dr. Shah holds board certification in hematology and oncology from the American Board of Internal Medicine.
Jatin Shah is 45, he's been the Executive Vice President、 Chief Medical Officer of Karyopharm Therapeutics Inc since 2019. There are 20 older and 2 younger executives at Karyopharm Therapeutics Inc. The oldest executive at Karyopharm Therapeutics Inc is Garen Bohlin, 72, who is the Independent Director.
Jatin's mailing address filed with the SEC is C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVE., NEWTON, MA, 02459.
Over the last 11 years, insiders at Karyopharm Therapeutics Inc have traded over 149,223,596$ worth of Karyopharm Therapeutics Inc stock and bought 562,763 units worth 10,312,371$ . The most active insiders traders include Deepika Pakianathan、Ltd Czernik Marcin Hadjimic...、Mikael Dolsten. On average, Karyopharm Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of 26,350$. The most recent stock trade was executed by Michael Mano on 4 September 2024, trading 3,971 units of KPTI stock currently worth 2,859$.
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com
Karyopharm Therapeutics Inc executives and other stock owners filed with the SEC include: